[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Baer et al., 2009 - Google Patents

Benzylic oxidation of gemfibrozil-1-O-β-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition

Baer et al., 2009

Document ID
14695881140539779501
Author
Baer B
DeLisle R
Allen A
Publication year
Publication venue
Chemical research in toxicology

External Links

Snippet

Gemfibrozil-1-O-β-glucuronide (GEM-1-O-gluc), a major metabolite of the antihyperlipidemic drug gemfibrozil, is a mechanism-based inhibitor of P450 2C8 in vitro, and this irreversible inactivation may lead to clinical drug− drug interactions between gemfibrozil and other P450 …
Continue reading at pubs.acs.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Similar Documents

Publication Publication Date Title
Baer et al. Benzylic oxidation of gemfibrozil-1-O-β-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition
Guengerich Cytochrome p450 and chemical toxicology
Argikar et al. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance
Kumar et al. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide
Zientek et al. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes
Hosea et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4
Zhou et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
Äbelö et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
Modi et al. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine as a Substrate of Cytochrome P450 2D6: Allosteric Effects of NADPH− Cytochrome P450 Reductase
Baer et al. Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate
Sevrioukova et al. Anion-dependent stimulation of CYP3A4 monooxygenase
Ratnam et al. The arginine 276 anchor for NADP (H) dictates fluorescence kinetic transients in 3α-hydroxysteroid dehydrogenase, a representative aldo− keto reductase
Sridar et al. Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein
Pearson et al. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates
Johnson et al. Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges
Sun et al. In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity
Jiang et al. Radical intermediates in the catalytic oxidation of hydrocarbons by bacterial and human cytochrome P450 enzymes
Sun et al. Metabolic activation of a novel 3-substituted indole-containing TNF-α inhibitor: dehydrogenation and inactivation of CYP3A4
Alvarez-Diez et al. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol
den Braver-Sewradj et al. Reduction and scavenging of chemically reactive drug metabolites by NAD (P) H: quinone oxidoreductase 1 and NRH: quinone oxidoreductase 2 and variability in hepatic concentrations
Xiong et al. Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis
Boerma et al. Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites
Wang et al. Unraveling the structural basis of selective inhibition of human cytochrome P450 3A5
Notley et al. Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its α-hydroxy and α, 4-dihydroxy derivatives
Milczek et al. Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B